Zobrazeno 1 - 10
of 326
pro vyhledávání: '"Paul Lorigan"'
Autor:
Bart Neyns, Christian U. Blank, Michal Lotem, Mark R. Middleton, J.-J. Grob, Melanie A. Leiby, Antoni Ribas, C. Robert, Jacob Schachter, Céleste Lebbé, Euan Walpole, Matteo S. Carlino, Neil Steven, Nageatte Ibrahim, Peter Mohr, A. Arance, Paul Lorigan, Mario Sznol, Erin Jensen, Georgina V. Long, Laurent Mortier
Publikováno v:
Long, G V, Arance, A, Mortier, L, Lorigan, P, Blank, C, Mohr, P, Schachter, J, Grob, J-J, Lotem, M, Middleton, M R, Neyns, B, Steven, N, Ribas, A, Walpole, E, Carlino, M S, Lebbe, C, Sznol, M, Jensen, E, Leiby, M A, Ibrahim, N & Robert, C 2022, ' Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma : analysis from KEYNOTE-006 ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 204-215 . https://doi.org/10.1016/j.annonc.2021.10.010
Background: Antitumor activity of ipilimumab or BRAF +/- MEK inhibitors (BRAFi +/- MEKi) following pembrolizumab administration in melanoma is poorly characterized. Patients and methods: In the phase III KEYNOTE-006 study, patients with unresectable
Autor:
Ann Tivey, Prerana Huddar, Rohan Shotton, Paul Lorigan, Susanna Daniels, Rebecca Lee, Imogen Cheese
Publikováno v:
Tivey, A, Huddar, P, Shotton, R, Cheese, I, Daniels, S, Lorigan, P & J Lee, R 2021, ' Patient engagement in melanoma research: from bench to bedside ', Future Oncology, vol. 17, no. 28, pp. 3705-3716 . https://doi.org/10.2217/fon-2020-1165
Advances in research have transformed the management of melanoma in the past decade. In parallel, patient advocacy has gained traction, and funders are increasingly prioritizing patient and public involvement. Here we discuss the ways in which patien
Autor:
C. Blank, Karijn P M Suijkerbuijk, Karlijn de Joode, Adriana Hepner, Céleste Lebbé, Yanina J L Jansen, Elisabeth G.E. de Vries, Andrew Haydon, Claudia Trojaniello, Lucy Storey, Paul Lorigan, Lauren Julia Brown, Alexander M. Menzies, Joanna Mangana, Astrid Aplonia Maria Van Der Veldt, Shahneen Sandhu, Bart Neyns, Douglas B. Johnson, Ellen Kapiteijn, Lisa Zimmer, Matteo S. Carlino, Georgina V. Long, Alison Weppler, Anne M. Hendriks, Harm van Tinteren, Judith M. Versluis, Mathilde Jalving, Victoria Atkinson, Prachi Bhave, Paolo A. Ascierto, Clara Allayous
Publikováno v:
European Journal of Cancer, 151, 72-83. Elsevier Ltd.
European Journal of Cancer, 151, 72-83. ELSEVIER SCI LTD
Versluis, J M, Hendriks, A M, Weppler, A M, Brown, L J, de Joode, K, Suijkerbuijk, K P M, Zimmer, L, Kapiteijn, E W, Allayous, C, Johnson, D B, Hepner, A, Mangana, J, Bhave, P, Jansen, Y J L, Trojaniello, C, Atkinson, V, Storey, L, Lorigan, P, Ascierto, P A, Neyns, B, Haydon, A, Menzies, A M, Long, G V, Lebbe, C, van der Veldt, A A M, Carlino, M S, Sandhu, S, van Tinteren, H, de Vries, E G E, Blank, C U & Jalving, M 2021, ' The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis ', European Journal of Cancer, vol. 151, pp. 72-83 . https://doi.org/10.1016/j.ejca.2021.04.003
European Journal of Cancer, 151, 72-83. ELSEVIER
European Journal of Cancer, 151, 72-83. ELSEVIER SCI LTD
Versluis, J M, Hendriks, A M, Weppler, A M, Brown, L J, de Joode, K, Suijkerbuijk, K P M, Zimmer, L, Kapiteijn, E W, Allayous, C, Johnson, D B, Hepner, A, Mangana, J, Bhave, P, Jansen, Y J L, Trojaniello, C, Atkinson, V, Storey, L, Lorigan, P, Ascierto, P A, Neyns, B, Haydon, A, Menzies, A M, Long, G V, Lebbe, C, van der Veldt, A A M, Carlino, M S, Sandhu, S, van Tinteren, H, de Vries, E G E, Blank, C U & Jalving, M 2021, ' The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis ', European Journal of Cancer, vol. 151, pp. 72-83 . https://doi.org/10.1016/j.ejca.2021.04.003
European Journal of Cancer, 151, 72-83. ELSEVIER
Introduction: In patients with metastatic melanoma, progression of a single tumour lesion (solitary progression) after response to immune checkpoint inhibition (ICI) is increasingly treated with local therapy. We evaluated the role of local therapy f
Autor:
Céleste Lebbé, Ines Pires da Silva, Irene L.M. Reijers, Megan Lyle, Alexander M. Menzies, Alison Weppler, Shahneen Sandhu, Camille L. Gerard, Matteo S. Carlino, Joanna Mangana, Douglas B. Johnson, Patricio Serra-Bellver, Oliver Klein, James R. Patrinely, Andrew Haydon, Tasnia Ahmed, Olivier Michielin, Khang Nguyen, Claudia Trojaniello, Paul Lorigan, Allison Betof Warner, Dan Stout, Clara Allayous, Christian U. Blank, Paolo A. Ascierto, Lisa Zimmer, Serigne Lo, Georgina V. Long
Publikováno v:
The Lancet Oncology. 22:836-847
Anti-PD-1 therapy (hereafter referred to as anti-PD-1) induces long-term disease control in approximately 30% of patients with metastatic melanoma; however, two-thirds of patients are resistant and will require further treatment. We aimed to determin
Autor:
Richard Marais, Grazia Saturno, Robert McLeary, Cyril Fisher, Udai Banerji, Alfonso Zambon, Lawrence Davies, Rebecca Lee, J.M.G. Larkin, Natasha Preece, Emma Dean, Paul Lorigan, Dan Niculescu-Duvaz, Matthew G Krebs, Amaya Viros, Nathalie Dhomen, Malin Pedersen, L. Johnson, Filipa Lopes, Caroline J. Springer, D. Holovanchuk, M. E. Gore, Ion Niculescu-Duvaz
Publikováno v:
Annals of Oncology
Saturno, G, Lopes, F, Niculescu-Duvaz, I, Niculescu-Duvaz, D, Zambon, A, Davies, L, Johnson, L, Preece, N, Lee, R, Viros Usandizaga, A, Holovanchuk, D, Pedersen, M, Mcleary, R, Lorigan, P, Dhomen, N, Fisher, C, Banerji, U, Dean, E, Krebs, M, Gore, M, Larkin, J, Marais, R & Springer, C 2021, ' The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers ', Annals of Oncology, vol. 32, no. 2, pp. 269-278 . https://doi.org/10.1016/j.annonc.2020.10.483
Saturno, G, Lopes, F, Niculescu-Duvaz, I, Niculescu-Duvaz, D, Zambon, A, Davies, L, Johnson, L, Preece, N, Lee, R, Viros Usandizaga, A, Holovanchuk, D, Pedersen, M, Mcleary, R, Lorigan, P, Dhomen, N, Fisher, C, Banerji, U, Dean, E, Krebs, M, Gore, M, Larkin, J, Marais, R & Springer, C 2021, ' The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers ', Annals of Oncology, vol. 32, no. 2, pp. 269-278 . https://doi.org/10.1016/j.annonc.2020.10.483
Background KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting G12CKRAS specifically, but therapeutic options for other mu
Autor:
Kristina V. Orlova, Mahtab Samimi, Paul Lorigan, Elena Benincasa, Nicola Fazio, Eyal Fenig, Vanna Chiarion Sileni, Paolo A. Ascierto, Nora Kramkimel, Ana Arance, Nuno Costa, Monika Dudzisz-Śledź, Oliver Bechter, Laurent Mortier, Giovanni Grignani, Lenka Kostkova, Christoffer Gebhardt, Neil Steven
Publikováno v:
Ascierto, P A, Orlova, K, Grignani, G, Dudzisz-Sledz, M, Fenig, E, Sileni, V C, Fazio, N, Samimi, M, Mortier, L, Gebhardt, C, Kramkimel, N, Steven, N, Bechter, O, Arance, A, Benincasa, E, Kostkova, L, Costa, N & Lorigan, P 2021, ' Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East ', International Journal of Cancer, vol. 149, no. 11, pp. 1926-1934 . https://doi.org/10.1002/ijc.33746
Incidence rates of Merkel cell carcinoma (MCC), an uncommon skin cancer with an aggressive disease course, have increased in recent decades. Limited treatment options are available for patients with metastatic MCC (mMCC). Avelumab, an anti-programmed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45d499a483301678f51b0eddc287ad25
https://doi.org/10.1002/ijc.33746
https://doi.org/10.1002/ijc.33746
Publikováno v:
European Journal of Cancer. 130:193-197
Introduction Immune-mediated toxicities are potentially fatal and can affect virtually any organ system. The prevalence of immune-mediated toxicity in patients being treated with immune checkpoint inhibitors (ICIs) is well described. However, the rea
Autor:
Philippa Middlehurst, Nathalie Dhomen, Richard Marais, Gabriela Gremel, John Weightman, Sarah Mills, Jeff Barry, Zena Salih, Avinash Gupta, Elena Galvani, Joshua Tweedy, Paul Lorigan, Antonia Banyard, Piyushkumar A. Mundra, Franziska Baenke, Sara Valpione
Publikováno v:
Nature cancer
Valpione, S, Galvani, E, Tweedy, J, Mundra, P A, Banyard, A, Middlehurst, P, Barry, J, Mills, S, Salih, Z, Weightman, J, Gupta, A, Gremel, G, Baenke, F, Dhomen, N, Lorigan, P C & Marais, R 2020, ' Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy ', Nature Cancer . https://doi.org/10.1038/s43018-019-0022-x
Valpione, S, Galvani, E, Tweedy, J, Mundra, P A, Banyard, A, Middlehurst, P, Barry, J, Mills, S, Salih, Z, Weightman, J, Gupta, A, Gremel, G, Baenke, F, Dhomen, N, Lorigan, P C & Marais, R 2020, ' Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy ', Nature Cancer . https://doi.org/10.1038/s43018-019-0022-x
Our understanding of how checkpoint inhibitors (CPIs) affect T cell evolution is incomplete, limiting our ability to achieve full clinical benefit from these drugs. Here, we analyzed peripheral T cell populations after one cycle of CPI treatment and
Autor:
Paul Lorigan, Rohit Thakur, Miles C. Andrews, Kate Hogan, Piyushkumar A. Mundra, Richard Marais, Martin G. Cook, Kang Zeng, Louis Boon, Antonia Banyard, Nathalie Dhomen, Matthew Smith, Jennifer A. Wargo, Jonathan Greenall, Elena Galvani, Garry Ashton, A. Mandal, Beth A. Helmink, Pablo Garcia-Martinez, Gabriela Gremel, Christopher P. E. Chester, Sara Valpione
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Galvani, E, Mundra, P A, Valpione, S, Garcia-Martinez, P, Smith, M, Greenall, J, Thakur, R, Helmink, B, Andrews, M C, Boon, L, Chester, C, Gremel, G, Hogan, K, Mandal, A, Zeng, K, Banyard, A, Ashton, G, Cook, M, Lorigan, P, Wargo, J A, Dhomen, N & Marais, R 2020, ' Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma ', Nature Communications, vol. 11, no. 1, pp. 853 . https://doi.org/10.1038/s41467-020-14632-2
Nature Communications
Galvani, E, Mundra, P A, Valpione, S, Garcia-Martinez, P, Smith, M, Greenall, J, Thakur, R, Helmink, B, Andrews, M C, Boon, L, Chester, C, Gremel, G, Hogan, K, Mandal, A, Zeng, K, Banyard, A, Ashton, G, Cook, M, Lorigan, P, Wargo, J A, Dhomen, N & Marais, R 2020, ' Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma ', Nature Communications, vol. 11, no. 1, pp. 853 . https://doi.org/10.1038/s41467-020-14632-2
Nature Communications
Although immune checkpoint inhibitors (ICIs) have achieved unprecedented results in melanoma, the biological features of the durable responses initiated by these drugs remain unknown. Here we show the genetic and phenotypic changes induced by treatme
Autor:
Rutger H. T. Koornstra, Sandrine Marreaud, Victoria Atkinson, Andrey Meshcheryakov, Christian U. Blank, Piotr Rutkowski, Jean-Jacques Grob, Leonel Hernandez-Aya, Clemens Krepler, Michal Kicinski, Dirk Schadendorf, Paolo A. Ascierto, Caroline Robert, Mario Mandalà, Susana Puig, Nageatte Ibrahim, Alexander C.J. van Akkooi, Adnan Khattak, Stéphane Dalle, Georgina V. Long, James Larkin, Shahneen Sandhu, Rahima Jamal, Matteo S. Carlino, Alfonsus J M van den Eertwegh, Ralf Gutzmer, Anna Maria Di Giacomo, Andrew Haydon, Alexander M.M. Eggermont, Stefan Suciu, Paul Lorigan
Publikováno v:
Journal of Clinical Oncology, 38, 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110
Journal of Clinical Oncology, 38, 33, pp. 3925-3936
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110
Journal of Clinical Oncology, 38(33), 3925-3936. American Society of Clinical Oncology
Journal of Clinical Oncology
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A M, Meshcheryakov, A, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, Di Giacomo, A M, van den Eertwegh, A J M, Grob, J J, Gutzmer, R, Jamal, R, Lorigan, P C, van Akkooi, A C J, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2020, ' Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma : Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, no. 33, pp. 3925-3936 . https://doi.org/10.1200/JCO.20.02110
Journal of Clinical Oncology, 38, 33, pp. 3925-3936
PURPOSE We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. On the basis of